Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aliskiren - Noden Pharma

Drug Profile

Aliskiren - Noden Pharma

Alternative Names: Aliskiren fumarate; Aliskiren hemi-fumarate; CGP 60536B; Enviage™; Rasilez; Rasilles; Riprazo™; SPP 100; SPP 100B; Sprimeo™; Tekturna

Latest Information Update: 23 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Amides; Antihypertensives; Fumarates; Small molecules
  • Mechanism of Action Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension
  • Discontinued Acute heart failure; Atherosclerosis; Chronic heart failure; Diabetic macular oedema; Diabetic nephropathies; Kidney disorders; Myocardial infarction

Most Recent Events

  • 10 Apr 2021 Discontinued - Phase-III for Chronic heart failure in Mexico, Costa Rica, Turkey, South Africa, Thailand, Japan, United Kingdom, Taiwan, Brazil, South Korea, Spain, Dominican Republic, Austria, Latvia, Switzerland, Romania, Dominican Republic, Czech Republic, Estonia, Russia, Belgium, Peru, South Korea, USA, Puerto Rico, Australia, Greece, Colombia, Argentina, India, Canada, China, France, Norway, Lithuania, Sweden, Slovakia, Netherlands, Venezuela, Ireland, Finland, Denmark, Germany, Italy, Poland, Portugal (PO)
  • 28 Sep 2020 Launched in Hypertension in Greece (PO, Tablets)
  • 07 Jul 2020 Launched in Hypertension in Hungary (PO, Tablets)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top